Published Date : 2025-Mar-19
The global patient blood management (PBM) market is projected to witness significant growth in 2025, driven by rising awareness about blood conservation, technological advancements in transfusion medicine, and an increasing prevalence of chronic diseases that require blood transfusion support.
The market growth is fueled by improved healthcare infrastructure, government initiatives promoting blood management, and innovations in blood transfusion technologies, diagnostic tools, and autotransfusion techniques.
An inventory control strategy that reduces waste and enables better protection of inventories, a training course that educates health professionals with optimal practices, and the creation of the most optimal treatment strategy for each patient based on multiple laboratory investigations are all components of a patient blood management program. Besides, most hospitals have put in place policies that govern appropriate treatment protocols when giving transfusions or conducting invasive procedures like dialysis or endoscopies. Lack of knowledge among medical practitioners regarding PBM, however, may be a setback to this business.
The basis of inpatient treatment is blood transfusions, but since blood supply and disease treatment are evolving so quickly, one must know how to conserve these supplies. "Conserved" is a resource with less adverse impact on morbidity or mortality than anticipated. Patient Blood Management (PBM) is becoming trendier because it seeks to decrease intraoperative blood transfusion using autologous blood products as much as possible, normalize their use, and maximize intravenous fluid postoperative care. It is also designed to minimize perioperative blood loss through judicious use of laboratory tests and clinical equipment. Loyal adherence to evidence-based protocols is still the most basic component of PBM. Optimization minimization of anemia care in the deficient patients is equally critical to the achievement of desired outcomes. These will also reduce the costs and perhaps reduce the number of allogenic blood donors, which would reduce the donor risks.
The following companies are recognized as key players in the PBM market:?
A newer creation of guidelines, Patient Blood Management is designed to safeguard the country's blood supply as well as patients' health. It attempts to safeguard these resources by reducing or eliminating autologous transfusions where possible, which will be cost saving and might mean fewer donors are needed per year. Evidence-based guidelines provide a means to assist physicians in achieving these goals and avoid the risks associated with making treatment decisions that are not supported by best practices or evidence.
Anemia, responsible for the death of one in every five deaths worldwide and almost half of all patient presentations to general practitioners each year, can be treated more effectively by the healthcare system with the help of patient blood management. Many diseases and conditions, such as heart failure, kidney disease, cancer, stroke, chronic obstructive pulmonary disease (COPD), and autoimmune diseases like rheumatoid arthritis, are forecasted to have poor prognoses by anemia. PBM guidelines for treatment are recognized by the Canadian Hematology Society as an effective measure for reducing unnecessary blood transfusions and enhancing hemoglobin control in patients with chronic disease.
PBM is supported by the American College of Critical Care Medicine (ACCM), which has opined that "transfusion of allogeneic blood products should be considered a therapeutic intervention aimed at securing hemostasis and the objectives of treatment must be accomplished without putting patients at increased risk of harm. An improvement of quality plan and not an approach of "bloodless medicine" is how the Canadian Medical Association Journal labelled as PBM. Every admission in a European hospital where close monitoring is adequate should receive an initial test dose of a vitamin K antagonist, according to the European Association for Hematology. They have also suggested that on oral anticoagulant therapy, the international normalized ratio (INR) should be checked every three months.
Besides being endorsed by international professional societies, PBM has also been endorsed by national patient organizations in the US and Norway.
About 10% of transfused patients in the hospital are transfused with donated blood rather than blood from a blood bank. Thus, blood banks are the largest consumers of patient blood management (PBM), using methods to collect and prepare about 14 million units of red blood cells to be transfused each year in the United States. Following the views of certain experts, PBM strategies will ultimately be utilized extensively with platelets since blood banks also get approximately 2 million units of platelets each year. Due to the limited shelf life and difficulty in storage of platelets, blood banks—a collection of organizations that collect, process, and transport blood to hospitals—are pushing for PBM methods to be developed using platelets.
Unlike red blood cells, platelets must be refrigerated at between 2 and 8 degrees Celsius (35- and 46-degrees Fahrenheit) and transfused within five days of collection. With reduced possibilities of side effects like febrile reaction, cerebral hemorrhage, and venous thrombosis, platelet PBM would allow cancer patients undergoing chemotherapy or surgery to receive more than usual platelets.
Most voluntary, non-remunerated blood donors—44.7 million—are from high-income countries, representing 57% of the more than 108 million blood donations that took place worldwide in 2015. Furthermore, in 2015, approximately 27 million units of blood components were donated globally. In 2019, the number reached 118.4 million units. Once collected, donated blood is often provided to patients a few days later. But blood can nonetheless be processed into a product which another individual may use even when it is stored for as much as six weeks.
The predominant providers of the supply have been found to be high-income countries. While 30% are from upper-middle-income countries, 21% are from lower middle-income countries, and 9% are from low-income countries, 40% of donors are from high-income countries.
Around 52.7 million men and 41.3 million women donated blood in 2015, of whom men comprised seven out of every ten blood donors in total. There were 19.6 million women who would donate in 2019; now there are 27.8 million more selfless males. Since it is widely accessible and spans all demographics and age groups, the voluntary unpaid donor group has been perceived as a powerful cushion for the worldwide health system.
There has been a notable presence of blood management in North America. Many academic institutions, research organizations, and private enterprises are investing heavily in developing new techniques for efficient cross-matching, rapid collecting, brief storage periods, and enhanced compatibility testing technologies. Many variables, including increasing demand for blood transfusions across North America, practitioners' increasing knowledge about safe transfusion practices, scientific technological advances, etc., all endorse such a trend.
Furthermore, the usage rate of blood management technologies has risen, especially for clinics and hospitals that utilize their blood bank to offer safe transfusion services. High growth in the geriatric population base in Canada and Mexico, increased platelet transfusion needs, increased demand for cord blood stem cells for transplants, and increased awareness among healthcare professionals about safe practices are some of the major drivers driving the market growth in North America. The demand for artificial blood substitutes and the sudden increase in blood transfusion procedures are the other key variables that are expected to influence this market growth. Additionally, the major sources of demand in this sector are healthcare facilities such as hospitals and clinics with blood banks, research institutions, academic institutions, and private enterprises.
Intellectual Market Insights Research is a global market intelligence and consulting organization that provides syndicated research reports, customized research reports, and consulting services. We are known for our actionable insights and authentic reports in various domains including, Semiconductor, aerospace, Automation, Agriculture, Food & Beverages, Automotive, Chemicals and Materials, and virtually all domains and an exhaustive list of sub-domains under the sun. We create value for clients through our highly reliable and accurate reports.
